Robert Dichmann

682 total citations
9 papers, 147 citations indexed

About

Robert Dichmann is a scholar working on Oncology, Hematology and Infectious Diseases. According to data from OpenAlex, Robert Dichmann has authored 9 papers receiving a total of 147 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Hematology and 3 papers in Infectious Diseases. Recurrent topics in Robert Dichmann's work include HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Robert Dichmann is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer Treatment and Pharmacology (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Robert Dichmann collaborates with scholars based in United States and France. Robert Dichmann's co-authors include Ralph V. Boccia, James R. Berenson, Ori Yellin, Youram Nassir, Dipti Patel‐Donnelly, James Hilger, Robert Vescio, Regina A. Swift, Shahrooz Eshaghian and Dennis J. Slamon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Robert Dichmann

9 papers receiving 145 citations

Peers

Robert Dichmann

ONCOL

HEMAT

PRM

RNMI

Klaus Kirchbacher Austria

Megan H. Jagosky United States

Sunil Gandhi United States

Wendy Crist United States

Karin H. Herbschleb United Kingdom

Donata Sartori Italy

Eric Zhi United States

Ivelise Rijo United States

Brett T. Brinker United States

Hans‐Günter Derigs Germany

Klaus Kirchbacher Austria

Robert Dichmann

48 ×0.5

ONCOL

35 ×0.5

35 ×0.7

HEMAT

51 ×1.6

PRM

21 ×1.0

RNMI

Citations per year, relative to Robert Dichmann Robert Dichmann (= 1×) peers Klaus Kirchbacher

Countries citing papers authored by Robert Dichmann

Since Specialization

Citations

This map shows the geographic impact of Robert Dichmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Dichmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Dichmann more than expected).

Fields of papers citing papers by Robert Dichmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Dichmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Dichmann. The network helps show where Robert Dichmann may publish in the future.

Co-authorship network of co-authors of Robert Dichmann

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Dichmann. A scholar is included among the top collaborators of Robert Dichmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Dichmann. Robert Dichmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Hurvitz, Sara A., Julie Taguchi, David W. Chan, et al.. (2018). Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Therapeutic Advances in Medical Oncology. 10. 3861422379–3861422379. 25 indexed citations

Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536. 55 indexed citations

Salles, Gilles, Thomas J. Ervin, Robert Dichmann, et al.. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).. Journal of Clinical Oncology. 32(15_suppl). TPS8620–TPS8620. 1 indexed citations

Berenson, James R., James Hilger, Robert Dichmann, et al.. (2013). Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8599–8599. 2 indexed citations

Berenson, James R., Ori Yellin, Robert Dichmann, et al.. (2012). A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.. Journal of Clinical Oncology. 30(15_suppl). 8098–8098. 5 indexed citations

Berenson, James R., James Hilger, Robert Dichmann, et al.. (2012). A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen. Blood. 120(21). 4063–4063. 1 indexed citations

Finn, RS, Katalin Boér, Roshni Patel, et al.. (2011). A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS100–TPS100. 4 indexed citations

Hurvitz, Sara A., Mark D. Pegram, David W. Chan, et al.. (2009). Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 6094–6094. 37 indexed citations

Slamon, DJ, John A. Glaspy, Mark D. Pegram, et al.. (2006). A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity. Journal of Clinical Oncology. 24(18_suppl). 10515–10515. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact